Source comparison
Tesamorelin + Ipa vs Tesamorelin + Ipamorelin Blend: Formulation Comparison
Chemical Composition Tesamorelin (GHRH analogue) + Ipamorelin (ghrelin mimetic) None. Identical active peptides Growth hormone studies, metabolic research, body composition protocols −20°C unreconstituted; 2–8°C post-reconstitution Naming Convention Abbreviate
This comparison does not assign a generated winner or score.
- Chemical Composition
- Tesamorelin (GHRH analogue) + Ipamorelin (ghrelin mimetic)
- None. Identical active peptides
- Growth hormone studies, metabolic research, body composition protocols
- −20°C unreconstituted; 2–8°C post-reconstitution
- Naming Convention
- Abbreviated form (Ipa shorthand for Ipamorelin)
- Full compound name
- Labelling only. No functional difference
- Both used interchangeably in research documentation
- Same for both formulations
- Mechanism of Action
- Dual-pathway GH modulation (synthesis + release)
- None. Mechanisms identical
- Synergistic GH elevation in controlled studies
- Typical Dosing Range
- 1–2mg total peptide per administration
- None. Dosing protocols identical
- Varies by study design and endpoints
- Reconstitution Protocol
- 2–3mL bacteriostatic water per 10mg total peptide
- None. Process identical
- Standard for all lyophilised peptide blends
- Professional Assessment
- Both names describe the same research-grade peptide formulation. The difference is nomenclature, not chemistry. Labs should verify total peptide content (mg per vial) rather than focusing on label phrasing.
- Same peptide blend regardless of abbreviated or full naming. Procurement decisions should prioritise supplier purity verification (HPLC/MS testing) and cold-chain integrity over label format.